Mature cystic ovarian teratoma with squamous cell carcinoma transformation: a case report and literature review.

IF 1.1 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY Hormone Molecular Biology and Clinical Investigation Pub Date : 2024-01-30 eCollection Date: 2024-03-01 DOI:10.1515/hmbci-2023-0001

Mahdi Abdoli Shadbad, Roghaiyeh Derogar, Ali Akbar Shekarchi, Farideh Akbari, Mehri Jafari Shobeiri

{"title":"Mature cystic ovarian teratoma with squamous cell carcinoma transformation: a case report and literature review.","authors":"Mahdi Abdoli Shadbad, Roghaiyeh Derogar, Ali Akbar Shekarchi, Farideh Akbari, Mehri Jafari Shobeiri","doi":"10.1515/hmbci-2023-0001","DOIUrl":null,"url":null,"abstract":"Objectives: Cancerous transformation in mature cystic ovarian teratoma is rare. Herein, we reported a case of squamous cell carcinoma transformation in mature cystic ovarian teratoma and performed an in-depth literature review to highlight the risk factors, prognosis, and suggested treatment for these patients.Case presentation: We report a 66-years old postmenopausal woman diagnosed with a 120×90 (mm) mass at the left adnexa compatible with mature cystic ovarian teratoma. Following resection, the histopathological investigations showed malignant transformation in her mature cystic ovarian teratoma, and the immunohistochemistry for cytokeratin (CK) 5/6 and tumor protein 63 (P63) indicated squamous cell carcinoma transformation. She has been observed for her stage IA tumor and has been cancer-free for 6 months.Conclusions: Although malignant transformation in mature cystic ovarian teratoma is rare, it should be suspected if certain risk factors, e.g., elderly and high tumor size, exist. Stage IA patients' prognosis is favorable, and chemotherapy is not recommended.","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2023-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Cancerous transformation in mature cystic ovarian teratoma is rare. Herein, we reported a case of squamous cell carcinoma transformation in mature cystic ovarian teratoma and performed an in-depth literature review to highlight the risk factors, prognosis, and suggested treatment for these patients.

Case presentation: We report a 66-years old postmenopausal woman diagnosed with a 120×90 (mm) mass at the left adnexa compatible with mature cystic ovarian teratoma. Following resection, the histopathological investigations showed malignant transformation in her mature cystic ovarian teratoma, and the immunohistochemistry for cytokeratin (CK) 5/6 and tumor protein 63 (P63) indicated squamous cell carcinoma transformation. She has been observed for her stage IA tumor and has been cancer-free for 6 months.

Conclusions: Although malignant transformation in mature cystic ovarian teratoma is rare, it should be suspected if certain risk factors, e.g., elderly and high tumor size, exist. Stage IA patients' prognosis is favorable, and chemotherapy is not recommended.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成熟囊性卵巢畸胎瘤伴鳞状细胞癌转化：病例报告和文献综述。

目的：成熟囊性卵巢畸胎瘤癌变非常罕见。在此，我们报告了一例成熟囊性卵巢畸胎瘤鳞状细胞癌转化病例，并进行了深入的文献综述，以强调此类患者的风险因素、预后和治疗建议：我们报告了一名66岁绝经后妇女的病例，她被诊断为左侧附件120×90（mm）肿块，符合成熟囊性卵巢畸胎瘤。切除术后，组织病理学检查显示她的成熟囊性卵巢畸胎瘤发生了恶性转化，细胞角蛋白（CK）5/6 和肿瘤蛋白 63（P63）的免疫组化显示为鳞状细胞癌转化。结论：虽然成熟性卵巢囊性畸胎瘤的恶性转化率较低，但其恶性程度却很高：结论：虽然成熟囊性卵巢畸胎瘤的恶性转化非常罕见，但如果存在某些危险因素，如老年人和肿瘤体积较大，则应怀疑其恶性转化。IA期患者预后良好，不建议化疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hormone Molecular Biology and Clinical Investigation BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

2.60

自引率

0.00%

发文量

期刊介绍： Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.